文献速递核素与放射性配体治疗肿瘤 PET/CT

诊疗一体化未来:核医学精准肿瘤学展望

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
PubMed 文献 · J Nucl Med · 2019-01-01

本文综述放射性药物治疗在精准肿瘤学中的发展,从1940年代131I治疗分化型甲状腺癌开始,重点介绍177Lu标记生长抑素类似物治疗神经内分泌肿瘤和PSMA靶向放射性核素治疗晚期前列腺癌,并描述放射标记抗体、神经降压素受体配体及FAP靶向药物等新型放射性药物的临床前和临床现状。

要点

  • 诊疗一体化利用肿瘤分子改变实现成像与治疗,已在神经内分泌肿瘤和前列腺癌中显著应用。
  • 新型放射性药物包括放射标记抗体、神经降压素受体配体及FAP抑制剂,处于临床前或早期临床阶段。

核心结论

  • 诊疗一体化在精准肿瘤学中已取得显著成就,并有多种新型放射性药物和靶点可供进一步临床研究。

研究设计与样本

  • 本文为综述,回顾了从1940年代131I治疗分化型甲状腺癌以来的核医学内放射治疗进展,并描述新型放射性药物的临床前和临床现状。

主要发现

  • 177Lu标记生长抑素类似物治疗神经内分泌肿瘤和PSMA靶向放射性核素治疗晚期前列腺癌已展示显著成就。
  • 131I-omburtamab靶向神经母细胞瘤细胞表面B7-H3蛋白,HuMab-5B1为89Zr/177Lu标记抗体治疗表达CA19-9的恶性肿瘤,177Lu-lilotomab为CD37抗体治疗B细胞淋巴瘤。
  • 111In/177Lu-3B-227神经降压素受体配体在多种恶性肿瘤(如胰腺腺癌)的成像和治疗中显示高潜力。
  • 68Ga-FAPI-04 PET成像正探索靶向成纤维细胞激活蛋白用于不同肿瘤实体,90Y-FAPI-04已有首批治疗应用。

临床怎么用

  • 利用放射性药物对肿瘤特定靶点进行成像与治疗的诊疗一体化原则,可用于晚期肿瘤的有效治疗且副作用低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular alterations in malignant disease result in the expression or upregulations of various targets that can be used for imaging and treatment with radiopharmaceuticals. This theranostic principle has acquired greater importance in personalized medicine in recent years, particularly in oncology, where advanced tumors can be treated effectively with low side effects. Since the pioneering use of 131I in differentiated thyroid cancer in the 1940s, remarkable achievements in nuclear medicine endoradiotherapy have been demonstrated, mainly in the treatment of neuroendocrine neoplasms by using 177Lu-labeled somatostatin analogs or in the treatment of advanced prostate cancer using prostate-specific membrane antigen-directed radionuclide therapy. Besides that, this review focuses on promising novel radiopharmaceuticals and describes their preclinical and clinical status. Radiolabeled antibodies, such as 131I-omburtamab directed against the B7-H3 protein on the surface of neuroblastoma cells; HuMab-5B1, a 89Zr/177Lu-labeled antibody for the treatment of CA19-9-expressing malignancies; and 177Lu-lilotomab, a CD37 antibody for the treatment of B-cell lymphomas, are being highlighted. The neurotensin receptor ligand 111In/177Lu-3B-227 has demonstrated high potential in imaging and therapy for several malignancies (e.g., pancreatic adenocarcinomas). Targeting of the fibroblast activation protein is currently being explored for different tumor entities using PET imaging with the fibroblast activation protein inhibitor (FAPI) 68Ga-FAPI-04, and the first therapeutic applications of 90Y-FAPI-04 have been applied. After 2 decades of rapid development in theranostics, a variety of new targets are available for further clinical investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Langbein T, Weber WA, Eiber M, et al. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019. PMID: 31481583. doi:10.2967/jnumed.118.220566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。